A biomarker is a protein or small molecule indicative of homeostasis or a disease state. As part of this Spotlight, we explore the different technologies used for biomarker discovery and what the future could hold.
Browsing: drug discovery
The demand for analyzing biomarkers in drug development has increased dramatically with the advancement of precision medicine. In this editorial Weiping Shao (Frontage) discusses the challenges and key advice for outsourcing biomarker research.
Drug discovery and development company, Evotec (Hamburg, Germany), enter a new collaboration agreement with Asia’s largest pharmaceutical company, Takeda (Tokyo, Japan), which promises to discover clinical candidates across multiple therapeutic areas.
In this editorial Helen Shen (QPS; PA, USA) discusses the projected growth in the global small molecule discovery market and what impact this may have on the management of chronic diseases as well as what to look for when partnering with a CRO for small molecule studies.
We look at some of the highlights of our Twitter chat (#TalkProteomics), where we questioned panelists John Wilson, Ben Orsburn, Matthias Trost and Eduardo Chicano Gálvez about all things proteomics – from mass spectrometry to drug discovery.
This editorial provides an insight into the development of proteomics as a tool for drug and biomarker discovery, pharmacodynamics and protein network elucidation; and where technology may be heading in the future.
Find out more about the latest news and developments in labs-on-chips in the investigation of gut inflammation and cellular responses in drug discovery in this round-up.
Find out more about the technologies involved in drug metabolism and what the future may hold for drug metabolism studies in drug discovery research in this ‘In the Zone’ feature.
As part of our focus, we present this podcast where we talk to Mark Savage who discusses how software tools can address certain challenges and bring forward compounds from discovery to development.
Quantitative whole body autoradiography (QWBA) and imaging mass spectrometry (IMS): can IMS replace QWBA to support regulated drug discovery and development
Read time: 4:45 mins
Eric Solon (Madrigal Pharmaceuticals; PA, USA) discusses whether or not IMS can replace QWBA as the technique of choice when examining the disposition of new drug and biotherapeutic entities.